AP NEWS

Global Xerostomia Therapeutics Market 2019-2023| Growing Focus on Biologics to Drive Demand| Technavio

January 6, 2019

LONDON--(BUSINESS WIRE)--Jan 6, 2019-- analysts forecast the global xerostomia therapeutics market to grow at a CAGR of over 3% during the forecast period, according to their latest market research report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190106005069/en/

Technavio forecasts the global xerostomia therapeutics market to grow at a CAGR of over 3% by 2023. (Graphic: Business Wire)

The growing focus on biologics is one of the major trends being witnessed in the . Biologics are pharmaceutical drug products that are manufactured from various biological sources. They are different from chemically manufactured pharmaceuticals. Biologics include vaccines, blood, blood components, monoclonal antibodies, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic proteins, and living cells used in cell therapy.

This report is available at a USD 1,000 discount for a limited time only:

According to Technavio analysts, one of the key factors contributing to the growth of the global xerostomia therapeutics market is the increasing awareness of xerostomia:

Global xerostomia therapeutics market: Increasing awareness of xerostomia

Xerostomia can be a symptom of various medical conditions or a side effect of radiation therapy to the head and neck areas. Hence, patients also need to be aware and proactive while speaking to their doctors about the signs and symptoms of xerostomia. Quick diagnosis of xerostomia is crucial due to the risk factors and symptoms of the condition. Additionally, the early detection of the condition can aid in treating xerostomia more effectively. Therefore, various government and non-government organizations are creating awareness about xerostomia with the aim of preventing delays in the diagnosis and overcoming the lack of awareness of treatment.

According to a senior analyst at Technavio for research on pharmaceuticals, “In countries such as the US, the Oral Cancer Foundation is creating awareness about the common causes for and the complications associated with xerostomia, as well as the signs and symptoms, diagnosis and evaluation of the condition and the available treatment options. Thus, the increase in the number of organizations and institutes involved in creating awareness of xerostomia among people is expected to drive the growth of the global xerostomia therapeutics market during the forecast period.”

Global xerostomia therapeutics market: Segmentation analysis

The global xerostomia therapeutics market research report provides market segmentation by product (OTC and prescription) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

The OTC segment held the largest market share in 2018, accounting for nearly 69% of the market. This product segment is expected to dominate the global market throughout the forecast period.

The Americas led the market in 2018 with a market share of over 39%. This region is expected to dominate the market through 2023, however, there will be a decrease in its market share.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

Market ecosystem Market characteristics Market segmentation analysis

Market Sizing

Market definition Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

Regional comparison Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendors covered Vendor classification Market positioning of vendors Competitive scenario

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20190106005069/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH RESEARCH SCIENCE GENERAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 01/06/2019 03:02 AM/DISC: 01/06/2019 03:02 AM

http://www.businesswire.com/news/home/20190106005069/en

AP RADIO
Update hourly